Solvias TLA technology supports the CMC aspects of IND filing
Customer Testimonial from GenVivo
"Solvias’ Targeted Locus Amplification (TLA) technology helped us determine the specific location of each product-associated gene in our Working Cell Bank and End of Production cells with precision and depth that were unattainable by a different whole genome sequencing approach. These data contributed to the conclusion that our cell line is genetically stable across our manufacturing process and were instrumental in supporting the CMC aspects of our IND filing for the product. The Solvias contacts were professional, personable, attentive, and helpful throughout every step of the study, from experimental design to finalization of the study report."
Cecilia Roh, Ph.D.
Senior Director of R&D at GenVivo
Discover how we empower clients like GenVivo. Download our sample report now!
Our Collaboration
GenVivo is a private, vertically-integrated biotechnology company founded to develop the latest novel gene delivery and immune stimulation therapies, which activate the patient’s immune system to treat cancers and prevent infectious diseases.
Solvias has worked closely with GenVivo for 3 years, supporting the quality control of their vector-based immunotherapy targeting hematologic malignancies ahead of regulatory filings and for use in patients. Specifically, Solvias’ Targeted Locus Amplification (TLA) assay, has been used as part of the quality control process for GenVivo product candidates to help characterize (multiple) vector integrity and genetic stability of their viral vector producing cell line.
We are proud to support GenVivo work as they advance their mission of developing and manufacturing products that are rapidly deployed, and easily administered, with the goal of increasing patient survival and improving quality of life.